Inari Medical has treated the first patient with its FlowTriever infusion aspiration system. The FlowTriever system received 510(k) marketing clearance from the US Food and Drug Administration (FDA) in February to treat emboli in the peripheral vasculature.
Tod Engelhardt, chairman of the Cardiovascular and Thoracic Surgery Division of East Jefferson General Hospital in Metairie, USA, said: “The FlowTriever offered an efficient, minimally invasive treatment and rapidly restored blood flow in the occluded vessel. I believe the FlowTriever is a promising new advancement in the treatment of vessels occluded by emboli.”
“The FlowTriever system is the first offering in Inari’s planned product portfolio,” said Bill Hoffman, Inari’s chief executive officer. “This device will be available for embolus treatment in peripheral applications at select centres and we plan to add additional centres as we gain clinical experience. We are pleased to provide a new tool for interventionalists to deal with emboli and rapidly restore flow in occluded vessels,” added Hoffman.